Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of “Buy” from Analysts

Annexon, Inc. (NASDAQ:ANNX) has been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $15.80.

A number of research analysts have recently commented on ANNX shares. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th.

Hedge Funds Weigh In On Annexon

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp increased its position in Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after purchasing an additional 2,068,294 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Annexon during the third quarter worth $8,484,000. Marshall Wace LLP raised its stake in Annexon by 436.6% during the second quarter. Marshall Wace LLP now owns 1,693,665 shares of the company’s stock worth $8,299,000 after buying an additional 1,378,053 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Annexon by 16.1% in the second quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock valued at $29,346,000 after buying an additional 832,617 shares during the period. Finally, Mutual of America Capital Management LLC bought a new stake in Annexon during the second quarter valued at $3,134,000.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $4.13 on Wednesday. Annexon has a one year low of $3.86 and a one year high of $8.40. The company has a market cap of $440.22 million, a price-to-earnings ratio of -3.93 and a beta of 1.11. The firm has a 50 day simple moving average of $4.95 and a 200 day simple moving average of $5.91.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.